Melanoma (Management and Treatment in Geriatric Patients)

Bolick NL, Geller AC. Epidemiology and Screening for Melanoma. Hematol Oncol Clin North Am. 2024.

Garbe C, Keim U, Eigentler TK, Amaral T, Katalinic A, Holleczek B, et al. Time trends in incidence and mortality of cutaneous melanoma in Germany. J Eur Acad Dermatol Venereol. 2019;33(7):1272-80.

Macdonald JB, Dueck AC, Gray RJ, Wasif N, Swanson DL, Sekulic A, et al. Malignant melanoma in the elderly: different regional disease and poorer prognosis. J Cancer. 2011;2:538-43.

Iglesias-Pena N, Paradela S, Tejera-Vaquerizo A, Boada A, Fonseca E. Cutaneous Melanoma in the Elderly: Review of a Growing Problem. Actas Dermo-Sifiliográficas (English Edition). 2019;110(6):434-47.

Caraban BM, Aschie M, Deacu M, Cozaru GC, Pundiche MB, Orasanu CI, et al. A Narrative Review of Current Knowledge on Cutaneous Melanoma. Clin Pract. 2024;14(1):214-41.

Balch CM, Soong S-J, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. Journal of Clinical Oncology. 2001;19(16):3622-34.

Council ML, Sheinbein DM. Common Skin Cancers in Older Adults Approach to Diagnosis and Management. Clin Geriatr Med. 2024;40(1):25-36.

Kaur A, Webster MR, Weeraratna AT. In the Wnt-er of life: Wnt signalling in melanoma and ageing. Br J Cancer. 2016;115(11):1273-9.

Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Coit DG, Atkins MB, et al. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013;20(12):3961-8.

Liu W, Dowling JP, Murray WK, McArthur GA, Thompson JF, Wolfe R, et al. Rate of Growth in Melanomas: Characteristics and Associations of Rapidly Growing Melanomas. Archives of Dermatology. 2006;142(12):1551-8.

Garcovich S, Colloca G, Sollena P, Andrea B, Balducci L, Cho WC, et al. Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric Oncology. Aging Dis. 2017;8(5):643-61.

Eljilany I, Castellano E, Tarhini AA. Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field. Cancers (Basel). 2023;15(16).

Ives NJ, Suciu S, Eggermont AMM, Kirkwood J, Lorigan P, Markovic SN, et al. Adjuvant interferon-alpha for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer. 2017;82:171-83.

Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002-14.

Iacono D, Vitale MG, Basile D, Pelizzari G, Cinausero M, Poletto E, et al. Immunotherapy for older patients with melanoma: From darkness to light? Pigment Cell Melanoma Res. 2021;34(3):550-63.

Elias R, Morales J, Rehman Y, Khurshid H. Immune Checkpoint Inhibitors in Older Adults. Curr Oncol Rep. 2016;18(8):47.

Johnston L, Starkey S, Mukovozov I, Robertson L, Petrella T, Alhusayen R. Surveillance After a Previous Cutaneous Melanoma Diagnosis: A Scoping Review of Melanoma Follow-Up Guidelines. J Cutan Med Surg. 2023;27(5):516-25.

Babbush KM, Damanpour S. Melanoma Diagnosis and Treatment in the Elderly. Current Geriatrics Reports. 2020;9(4):199-205.

Sabel MS, Lee J, Cai S, Englesbe MJ, Holcombe S, Wang S. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol. 2011;18(13):3579-85.